12 Best Multibagger Stocks to Buy Heading into 2026

Page 9 of 11

3. Palvella Therapeutics, Inc. (NASDAQ:PVLA)

Market Cap: $1.15 Billion

Price Return over 1-Year: 607.77%

Upside Potential: 106.50%

Number of Hedge Fund Holders: 16

With strong 1-year returns and upside potential, Palvella Therapeutics, Inc. (NASDAQ:PVLA) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026.

On December 16, 2025, analyst confidence in Palvella Therapeutics, Inc. (NASDAQ:PVLA) was seen rising, as the company announced encouraging Phase 2 data for QTORIN rapamycin in cutaneous venous malformations (cVM).

The Fly reported that Palvella Therapeutics, Inc. (NASDAQ:PVLA) saw Canaccord analyst Whitney Ijem raise the firm’s target from $148 to $204, while reiterating a “Buy” rating. The analyst believes the better-than-expected improvement on the cVM-IGA at Week 12 should enable an efficient, lower-cost pivotal trial design. While management had targeted at least a 30% response rate, the firm noted that the improvement far exceeded expectations.

On the same day, Palvella Therapeutics, Inc. (NASDAQ:PVLA) also saw Truist raising its price target from $105 to $190, while maintaining a “Buy” rating. Incorporating risk-adjusted cVM sales into its model, the bank noted that the small proof-of-concept study meaningfully de-risked the opportunity. Additionally, Truist believes observed efficacy may not fully reflect the treatment effect, with responses appearing to deepen over time.

Palvella Therapeutics, Inc. (NASDAQ:PVLA) announced its positive topline Phase 2 TOIVA data on December 15, demonstrating broad clinical improvement and favorable tolerability.

On December 16, 2025, Palvella Therapeutics, Inc. (NASDAQ:PVLA) announced that the FDA granted Fast Track designation to QTORIN rapamycin for angiokeratomas. This regulatory win reinforces the company’s expanding development path and regulatory visibility.

Palvella Therapeutics, Inc. (NASDAQ:PVLA) is focused on developing novel topical therapies for serious, rare skin diseases. Its pipeline is led by the QTORIN platform, which targets conditions including venous malformations and angiokeratomas.

Page 9 of 11